FDA-approved Drug Cracks Cancer’s Defense

A close-up view of a variety of colorful pills and tablets stacked together

A deadly liver cancer that strikes mostly young adults has been hiding from the immune system — and researchers just found the door it uses to escape.

Story Snapshot

Fibrolamellar carcinoma traps immune cells at the edge of tumors, blocking them from killing cancer cells inside.
Cornell University researchers found that an existing FDA-approved drug called AMD3100 breaks that trap and lets immune cells enter the tumor core.
When AMD3100 was combined with immunotherapy in patient tumor slice tests, tumor cell death increased significantly.
No human clinical trials have started yet — researchers are still searching for clinicians to run them.

A Cancer That Mostly Strikes the Young — and Has No Good Treatment

Fibrolamellar carcinoma is a rare liver cancer that mostly hits teens and young adults with no history of liver disease. That alone makes it unusual. What makes it devastating is the lack of options. Standard liver cancer drugs barely work on it. Immunotherapy — the treatment that has transformed survival rates for melanoma and lung cancer — shows only modest results here too, with just a 15.8% response rate in the largest study done on it. ^[4] Patients and families have been waiting for something better for a long time.

The core problem has stumped researchers for years. Immunotherapy works by unleashing the body’s own T cells — the immune system’s attack force — to hunt and kill cancer cells. But in fibrolamellar carcinoma, something stops T cells from doing their job. They show up to the fight and then just… stop at the door. Understanding why that happens turned out to be the key to everything.

How the Tumor Builds a Wall Against the Immune System

Cornell University researchers published a study on February 17, 2026 in the journal Gastroenterology that explains the mechanism clearly. Fibrolamellar tumors create what the researchers describe as an immune “no entry” zone. T cells arrive at the tumor but get penned in at the outer edges. They never reach the cancer cells inside. The tumor essentially uses the body’s own chemistry to keep its attackers locked out. ^[1]

The specific culprit is a process called T-cell sequestration. The tumor traps T cells before they can penetrate the core. AMD3100 — a drug already approved by the Food and Drug Administration (FDA) for a bone marrow condition — blocks that sequestration process. When researchers tested AMD3100 on actual patient tumor slices, T cells moved into the tumor core where they had never gone before. ^[1] That is not a minor finding. That is the lock being picked.

Combining AMD3100 With Immunotherapy Produced a Clear Result

Testing AMD3100 alone was not the end goal. The Cornell team combined it with immune checkpoint inhibitors — the class of immunotherapy drugs that already exist for cancer treatment. The result was a significant increase in tumor cell death compared to either treatment alone. ^[1] The University of Washington team, led by the Pillarisetty research group, used patient tumor slices to confirm that AMD3100 effectively mobilized T cells into the tumor core. Two independent teams, same conclusion. That kind of confirmation matters in early-stage research.

The FDA-approval status of AMD3100 is a real advantage here, not just a talking point. Prashanth Sethupathy, the Cornell researcher leading this work, said directly that the drug’s existing approval “can reduce risks and potentially speed up timelines for clinical trials” in fibrolamellar carcinoma. ^[1] Repurposing approved drugs for new cancer indications is a well-worn path in oncology. Research published in Nature found the average time between a drug’s first approval and its repurposing for a new use is 7.2 years — far shorter than developing a new drug from scratch. ^[13]

What the Research Still Cannot Tell Us

This is where honest reporting matters. The tumor slice tests are promising, but they are not human clinical trials. No patient has been treated with this combination yet. There is no data on how long responses last, whether patients live longer, or what side effects emerge when AMD3100 is combined with checkpoint inhibitors in this specific disease. The researchers themselves are still searching for liver cancer clinicians willing to run those trials. ^[1] The science points in a clear direction. The proof has not arrived yet.

The rarity of fibrolamellar carcinoma also creates a real obstacle. The largest study of immunotherapy in this cancer involved just 19 patients. ^[4] Running a clinical trial with enough patients to produce reliable data will take time and coordination across multiple medical centers. The FDA is actively seeking ideas for repurposing approved drugs to address rare diseases with unmet needs, which creates a favorable environment for moving this research forward. But favorable environments and finished clinical trials are two different things. The patients who need this cannot afford to confuse one for the other.